{"product_id":"ew-vrio-analysis","title":"Edwards Lifesciences Corporation (EW): VRIO Analysis [June-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eGet a ready-made VRIO Analysis of Edwards Lifesciences Corporation Business that shows you how its key resources and capabilities create competitive advantage. You’ll learn why its global TAVR leadership, with roughly \u003cstrong\u003e60%\u003c\/strong\u003e global share, transcatheter mitral and tricuspid innovation, clinical trial strength, IP defense, regulatory access, manufacturing, and commercial network support mostly sustained advantages, while financial flexibility is only a temporary one. This is a practical study aid for essays, case studies, presentations, and research on how Edwards Lifesciences Corporation Business builds and protects value.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eEdwards Lifesciences Corporation - VRIO Analysis: First Core Capabilities \/ Resources: Global TAVR leadership and brand\u003c\/h2\u003e\n\u003cp\u003eGlobal TAVR leadership is a VRIO-positive resource for Edwards Lifesciences Corporation because a \u003cstrong\u003e60%\u003c\/strong\u003e global share and a \u003cstrong\u003e2011\u003c\/strong\u003e U.S. approval base create value, rarity, and switching costs.\u003c\/p\u003e\n\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003e60%\u003c\/strong\u003e global share supports physician trust, procedure volume, and pricing power in structural heart.\u003c\/p\u003e\n\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eA \u003cstrong\u003e60%\u003c\/strong\u003e global share is uncommon in medtech leadership positions.\u003c\/p\u003e\n\n\u003ch3\u003eInimitability\u003c\/h3\u003e\n\u003cp\u003eThe moat reflects a \u003cstrong\u003e13-year\u003c\/strong\u003e commercial base from \u003cstrong\u003e2011\u003c\/strong\u003e to \u003cstrong\u003e2024\u003c\/strong\u003e, plus installed base, clinical reputation, training depth, and switching costs.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eIn \u003cstrong\u003e2024\u003c\/strong\u003e, Edwards Lifesciences Corporation was organized around TAVR commercialization, evidence generation, and access expansion.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003eVRIO element\u003c\/th\u003e\n    \u003cth\u003eReal-life numeric data\u003c\/th\u003e\n    \u003cth\u003eBusiness impact\u003c\/th\u003e\n    \u003cth\u003eVRIO result\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eValue\u003c\/td\u003e\n    \u003ctd\u003e\n\u003cstrong\u003e60%\u003c\/strong\u003e; \u003cstrong\u003e2011\u003c\/strong\u003e\n\u003c\/td\u003e\n    \u003ctd\u003ePhysician trust, procedure volume, pricing power\u003c\/td\u003e\n    \u003ctd\u003eYes\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eRarity\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e60%\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eRare in medtech leadership\u003c\/td\u003e\n    \u003ctd\u003eYes\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eInimitability\u003c\/td\u003e\n    \u003ctd\u003e\n\u003cstrong\u003e13\u003c\/strong\u003e; \u003cstrong\u003e2011\u003c\/strong\u003e; \u003cstrong\u003e2024\u003c\/strong\u003e\n\u003c\/td\u003e\n    \u003ctd\u003eInstalled base, clinical reputation, switching costs\u003c\/td\u003e\n    \u003ctd\u003eYes\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eOrganization\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e2024\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eCommercialization, evidence generation, access expansion\u003c\/td\u003e\n    \u003ctd\u003eYes\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eCompetitive advantage\u003c\/td\u003e\n    \u003ctd\u003e\n\u003cstrong\u003e60%\u003c\/strong\u003e; \u003cstrong\u003e13\u003c\/strong\u003e\n\u003c\/td\u003e\n    \u003ctd\u003eSustained\u003c\/td\u003e\n    \u003ctd\u003eYes\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n  \u003cli\u003e\n\u003cstrong\u003e60%\u003c\/strong\u003e global share\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e2011\u003c\/strong\u003e U.S. approval\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e13\u003c\/strong\u003e years of commercial history through \u003cstrong\u003e2024\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eEdwards Lifesciences Corporation - VRIO Analysis: Second Core Capabilities \/ Resources: Transcatheter mitral and tricuspid innovation platform\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003e5\u003c\/strong\u003e named programs; \u003cstrong\u003e2\u003c\/strong\u003e valve targets; \u003cstrong\u003e1\u003c\/strong\u003e FDA approval in \u003cstrong\u003e2024\u003c\/strong\u003e; \u003cstrong\u003e400\u003c\/strong\u003e patients in TRISCEND II.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eVRIO element\u003c\/th\u003e\n\u003cth\u003eReal-life number or fact\u003c\/th\u003e\n\u003cth\u003eResult\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e5\u003c\/strong\u003e programs across \u003cstrong\u003e2\u003c\/strong\u003e valve targets\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e1\u003c\/strong\u003e FDA-approved transcatheter tricuspid system in \u003cstrong\u003e2024\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e400\u003c\/strong\u003e-patient pivotal trial\u003c\/td\u003e\n\u003ctd\u003eDifficult\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e5\u003c\/strong\u003e programs aligned behind one platform\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e5\u003c\/strong\u003e named programs: EVOQUE, SAPIEN M3, SOJOURN, JOURNEY, TRIFORMIS.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e2\u003c\/strong\u003e valve targets: mitral and tricuspid.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e400\u003c\/strong\u003e patients in TRISCEND II.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e1\u003c\/strong\u003e FDA approval for EVOQUE in \u003cstrong\u003e2024\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e4\u003c\/strong\u003e additional named programs in the platform.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e400\u003c\/strong\u003e-patient pivotal trial scale raises the entry barrier.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e2024\u003c\/strong\u003e approval shows the regulatory threshold.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e5\u003c\/strong\u003e programs under one platform.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e1\u003c\/strong\u003e commercial approval in \u003cstrong\u003e2024\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003eSustained.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eEdwards Lifesciences Corporation - VRIO Analysis: Third Core Capabilities \/ Resources: Surgical structural heart portfolio and RESILIA tissue\n\u003c\/h2\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eVRIO element\u003c\/td\u003e\n    \u003ctd\u003eReal-life numbers\u003c\/td\u003e\n    \u003ctd\u003eAssessment\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eValue\u003c\/td\u003e\n    \u003ctd\u003e\n\u003cstrong\u003e2\u003c\/strong\u003e commercial RESILIA surgical valve lines; \u003cstrong\u003e3\u003c\/strong\u003e valve positions\u003c\/td\u003e\n    \u003ctd\u003eYes\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eRarity\u003c\/td\u003e\n    \u003ctd\u003e\n\u003cstrong\u003e689\u003c\/strong\u003e-patient COMMENCE study; \u003cstrong\u003e5\u003c\/strong\u003e-year follow-up\u003c\/td\u003e\n    \u003ctd\u003eYes\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eInimitability\u003c\/td\u003e\n    \u003ctd\u003e\n\u003cstrong\u003e5\u003c\/strong\u003e-year clinical data; biomaterial validation\u003c\/td\u003e\n    \u003ctd\u003eModerately difficult\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eOrganization\u003c\/td\u003e\n    \u003ctd\u003e\n\u003cstrong\u003e2\u003c\/strong\u003e integrated RESILIA surgical valve lines\u003c\/td\u003e\n    \u003ctd\u003eYes\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eCompetitive advantage\u003c\/td\u003e\n    \u003ctd\u003eSustained\u003c\/td\u003e\n    \u003ctd\u003eSustained\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n  \u003cli\u003e\n\u003cstrong\u003e2\u003c\/strong\u003e commercial RESILIA surgical valve lines: INSPIRIS RESILIA and MITRIS RESILIA\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e3\u003c\/strong\u003e valve positions: aortic, mitral, tricuspid\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e689\u003c\/strong\u003e patients in COMMENCE\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e5\u003c\/strong\u003e-year follow-up\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003e2\u003c\/strong\u003e RESILIA surgical valve lines and \u003cstrong\u003e3\u003c\/strong\u003e valve positions.\u003c\/p\u003e\n\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003e689\u003c\/strong\u003e patients and \u003cstrong\u003e5\u003c\/strong\u003e-year follow-up.\u003c\/p\u003e\n\n\u003ch3\u003eInimitability\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003e5\u003c\/strong\u003e-year clinical data.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003e2\u003c\/strong\u003e integrated commercial RESILIA valve lines.\u003c\/p\u003e\n\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003eSustained.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eEdwards Lifesciences Corporation - VRIO Analysis: Fourth Core Capabilities \/ Resources: Clinical evidence generation and trial execution\u003c\/h2\u003e\n\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003e1,000\u003c\/strong\u003e-patient PARTNER 3 and \u003cstrong\u003e901\u003c\/strong\u003e-patient EARLY TAVR trials create the evidence base used for approvals, guideline adoption, payer coverage, and market expansion.\u003c\/p\u003e\n\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eEdwards has \u003cstrong\u003e3\u003c\/strong\u003e named programs in this capability set: COMMENCE, EARLY TAVR, and PROGRESS.\u003c\/p\u003e\n\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003eStructural heart pivotal trial execution at \u003cstrong\u003e1,000\u003c\/strong\u003e and \u003cstrong\u003e901\u003c\/strong\u003e patient scale is difficult to copy because it depends on multicenter enrollment, key opinion leader access, and trial operations.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eEdwards is organized to fund and structure repeated evidence generation across \u003cstrong\u003e3\u003c\/strong\u003e major studies, with PARTNER 3 at \u003cstrong\u003e1,000\u003c\/strong\u003e patients and EARLY TAVR at \u003cstrong\u003e901\u003c\/strong\u003e patients.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eVRIO element\u003c\/th\u003e\n\u003cth\u003eReal-life evidence\u003c\/th\u003e\n\u003cth\u003eNumber\u003c\/th\u003e\n\u003cth\u003eAssessment\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003ePARTNER 3; EARLY TAVR\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e1,000\u003c\/strong\u003e; \u003cstrong\u003e901\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003eNamed programs\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e3\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability\u003c\/td\u003e\n\u003ctd\u003eRandomized trial design\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1:1\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eHard\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003eCOMMENCE; EARLY TAVR; PROGRESS\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e3\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetitive advantage\u003c\/td\u003e\n\u003ctd\u003eClinical evidence engine\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eSustained\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSustained\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cul\u003e\n\u003cli\u003ePARTNER 3: \u003cstrong\u003e1,000\u003c\/strong\u003e patients\u003c\/li\u003e\n\u003cli\u003eEARLY TAVR: \u003cstrong\u003e901\u003c\/strong\u003e patients\u003c\/li\u003e\n\u003cli\u003eNamed programs: \u003cstrong\u003e3\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eRandomized design: \u003cstrong\u003e1:1\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eEdwards Lifesciences Corporation - VRIO Analysis: Fifth Core Capabilities \/ Resources: Intellectual property and legal defense\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003e20\u003c\/strong\u003e-year patent life and \u003cstrong\u003e68\u003c\/strong\u003e years since \u003cstrong\u003e1958\u003c\/strong\u003e support product exclusivity across \u003cstrong\u003e2\u003c\/strong\u003e key legal regions: the U.S. and Europe.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eVRIO test\u003c\/td\u003e\n    \u003ctd\u003eReal-life number\u003c\/td\u003e\n    \u003ctd\u003eDirect effect\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eValue\u003c\/td\u003e\n    \u003ctd\u003e\n\u003cstrong\u003e20\u003c\/strong\u003e-year patent term\u003c\/td\u003e\n    \u003ctd\u003eExclusivity window\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eRarity\u003c\/td\u003e\n    \u003ctd\u003e\n\u003cstrong\u003e1958\u003c\/strong\u003e founding year\u003c\/td\u003e\n    \u003ctd\u003e\n\u003cstrong\u003e68\u003c\/strong\u003e years of accumulated IP history by \u003cstrong\u003e2026\u003c\/strong\u003e\n\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eImitability\u003c\/td\u003e\n    \u003ctd\u003e\n\u003cstrong\u003e2\u003c\/strong\u003e regions\u003c\/td\u003e\n    \u003ctd\u003eU.S. and Europe legal defense is difficult to copy quickly\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eOrganization\u003c\/td\u003e\n    \u003ctd\u003e\n\u003cstrong\u003e2\u003c\/strong\u003e regions\u003c\/td\u003e\n    \u003ctd\u003eIP defense can be organized across the U.S. and Europe\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eCompetitive advantage\u003c\/td\u003e\n    \u003ctd\u003eSustained\u003c\/td\u003e\n    \u003ctd\u003ePatent life plus long operating history\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n  \u003cli\u003e\n\u003cstrong\u003e20\u003c\/strong\u003e: patent term from filing.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e1958\u003c\/strong\u003e: founding year.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e68\u003c\/strong\u003e: years of operating history in \u003cstrong\u003e2026\u003c\/strong\u003e.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e2\u003c\/strong\u003e: U.S. and Europe.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eEdwards Lifesciences Corporation - VRIO Analysis: Sixth Core Capabilities \/ Resources: Regulatory and reimbursement access capability\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003e2024\u003c\/strong\u003e FDA approval and a \u003cstrong\u003e400\u003c\/strong\u003e-patient pivotal trial show that this capability converts clinical evidence into market access.\u003c\/p\u003e\n\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003e400\u003c\/strong\u003e TRISCEND II patients and \u003cstrong\u003e1\u003c\/strong\u003e FDA approval in \u003cstrong\u003e2024\u003c\/strong\u003e support faster approval pathways and broader patient access.\u003c\/p\u003e\n\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eBy \u003cstrong\u003e2024\u003c\/strong\u003e, Edwards had \u003cstrong\u003e2\u003c\/strong\u003e U.S. transcatheter structural-heart approvals across mitral and tricuspid therapy areas.\u003c\/p\u003e\n\n\u003ch3\u003eInimitability\u003c\/h3\u003e\n\u003cp\u003eCopying this requires \u003cstrong\u003e400\u003c\/strong\u003e-patient evidence packages, FDA review, and payer dossiers; that takes years.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e2024\u003c\/strong\u003e FDA approval\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e2\u003c\/strong\u003e U.S. approvals by \u003cstrong\u003e2024\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e400\u003c\/strong\u003e pivotal-trial patients\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eVRIO element\u003c\/th\u003e\n\u003cth\u003eReal-life number\u003c\/th\u003e\n\u003cth\u003eBusiness meaning\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e400\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eClinical evidence base for approval\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eU.S. transcatheter approvals by \u003cstrong\u003e2024\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2024\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eApproval-cycle execution\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003eSustained.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eEdwards Lifesciences Corporation - VRIO Analysis: Seventh Core Capabilities \/ Resources: High-precision manufacturing and supply chain\n\u003c\/h2\u003e\n\u003cp\u003eEdwards Lifesciences Corporation’s high-precision manufacturing and supply chain is a sustained advantage because it supports clinical consistency, supply reliability, and margin discipline.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eVRIO test\u003c\/th\u003e\n\u003cth\u003eReal-life number\u003c\/th\u003e\n\u003cth\u003eAssessment\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1958\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eLong operating history supports validated manufacturing learning and reliable implant supply.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2024\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eStructural heart manufacturing still requires tight quality systems and precision control at global scale.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1958\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eProcess learning, validation, and regulatory oversight make replication slow and costly.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2024\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eEdwards Lifesciences Corporation appears structured to operate globally despite FX and tariff pressure.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetitive advantage\u003c\/td\u003e\n\u003ctd\u003eSustained\u003c\/td\u003e\n\u003ctd\u003eThe resource is valuable, rare, hard to copy, and supported by the organization.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003eHigh-precision manufacturing matters because implant quality has direct clinical impact. For Edwards Lifesciences Corporation, this capability helps protect supply continuity and support gross margins through lower defect and disruption risk.\u003c\/p\u003e\n\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eThis is rare because structural heart devices require strict tolerances, validated processes, and quality control systems that are hard for most manufacturers to match.\u003c\/p\u003e\n\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003eCompetitors can buy equipment, but they cannot quickly copy years of process learning, regulatory validation, and execution discipline across the supply chain.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eEdwards Lifesciences Corporation appears organized to use this capability at global scale, even with FX and tariff pressure.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003e1958\u003c\/strong\u003e founding year\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e2024\u003c\/strong\u003e current operating context\u003c\/li\u003e\n\u003cli\u003eSustained advantage: yes\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eEdwards Lifesciences Corporation - VRIO Analysis: Eight Core Capabilities \/ Resources: Global commercial network and physician adoption engine\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003e$5.4 billion\u003c\/strong\u003e and \u003cstrong\u003e$1.6 billion\u003c\/strong\u003e.\u003c\/p\u003e\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eVRIO\u003c\/th\u003e\n\u003cth\u003eNumber\u003c\/th\u003e\n\u003cth\u003eReference point\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$5.4 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2024 net sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.6 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2024 SG\u0026amp;A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e66\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e1958 to 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e24\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2000 to 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cul\u003e\n\u003cli\u003e\u003cstrong\u003e$5.4 billion\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003e$1.6 billion\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003e66\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003e24\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eEdwards Lifesciences Corporation - VRIO Analysis: Ninth Core Capabilities \/ Resources: Financial flexibility and capital allocation discipline\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003e$4.6B\u003c\/strong\u003e in cash, cash equivalents, and short-term investments, plus \u003cstrong\u003e$1.9B\u003c\/strong\u003e in operating cash flow and \u003cstrong\u003e$1.0B\u003c\/strong\u003e in R\u0026amp;D spending in 2023, make this resource valuable for funding growth, buybacks, and volatility absorption.\u003c\/p\u003e\n\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003e$1.0B\u003c\/strong\u003e in R\u0026amp;D and \u003cstrong\u003e$600M\u003c\/strong\u003e in share repurchases show direct use of internal cash for growth and capital return.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n  \u003cli\u003e\n\u003cstrong\u003e$4.6B\u003c\/strong\u003e liquidity buffer\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e$1.9B\u003c\/strong\u003e operating cash flow\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e$600M\u003c\/strong\u003e share repurchases\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eMetric\u003c\/td\u003e\n    \u003ctd\u003e2023 amount\u003c\/td\u003e\n    \u003ctd\u003eVRIO relevance\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eCash, cash equivalents, and short-term investments\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e$4.6B\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eFunds R\u0026amp;D and absorbs volatility\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eNet cash from operating activities\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e$1.9B\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eSupports buybacks and M\u0026amp;A optionality\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eResearch and development expense\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e$1.0B\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eSustains product pipeline\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eShare repurchases\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e$600M\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eShows capital allocation discipline\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003e$4.6B\u003c\/strong\u003e of liquidity is helpful, but similar cash strength exists at other large medtech companies, so this is only somewhat rare.\u003c\/p\u003e\n\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003e$1.9B\u003c\/strong\u003e in operating cash flow and \u003cstrong\u003e$600M\u003c\/strong\u003e in repurchases are matchable over time by stronger rivals, so this is not a deep moat.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eYes; Edwards uses capital actively through \u003cstrong\u003e$600M\u003c\/strong\u003e in repurchases and \u003cstrong\u003e$1.0B\u003c\/strong\u003e in R\u0026amp;D funding while keeping a large cash base.\u003c\/p\u003e\n\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003eTemporary.\u003c\/p\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516161548437,"sku":"ew-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/ew-vrio-analysis.png?v=1740169085","url":"https:\/\/dcf-model.com\/products\/ew-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}